ArriVent BioPharma Reports Third Quarter 2024 Financial Results
Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastasesTop-line pivotal data ...
SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 - - Data from the Phase 2a Trial of SLS009 in Relapse ...